Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

doi:10.1016/j.vaccine.2018.11.004

Review

. 2019 Oct 3:37 Suppl 1:A132-A139.

doi: 10.1016/j.vaccine.2018.11.004. Epub 2018 Nov 29.

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

Erin Sparrow¹, Siranda Torvaldsen², Anthony T Newall³, James G Wood³, Mohamud Sheikh³, Marie Paule Kieny⁴, Bernadette Abela-Ridder⁵

Affiliations

¹ The World Health Organization, Geneva, Switzerland; School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia. Electronic address: sparrowe@who.int.
² School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia; Clinical and Population Perinatal Health Research, The University of Sydney Northern Clinical School, NSW, Australia.
³ School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia.
⁴ Institut national de la santé et de la recherche médicale, Paris, France.
⁵ The World Health Organization, Geneva, Switzerland.

PMID: 30503659
DOI: 10.1016/j.vaccine.2018.11.004

Free article

Review

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

Erin Sparrow et al. Vaccine. 2019.

Free article

. 2019 Oct 3:37 Suppl 1:A132-A139.

doi: 10.1016/j.vaccine.2018.11.004. Epub 2018 Nov 29.

Authors

Erin Sparrow¹, Siranda Torvaldsen², Anthony T Newall³, James G Wood³, Mohamud Sheikh³, Marie Paule Kieny⁴, Bernadette Abela-Ridder⁵

Affiliations

¹ The World Health Organization, Geneva, Switzerland; School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia. Electronic address: sparrowe@who.int.
² School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia; Clinical and Population Perinatal Health Research, The University of Sydney Northern Clinical School, NSW, Australia.
³ School of Public Health and Community Medicine, UNSW Sydney, NSW, Australia.
⁴ Institut national de la santé et de la recherche médicale, Paris, France.
⁵ The World Health Organization, Geneva, Switzerland.

PMID: 30503659
DOI: 10.1016/j.vaccine.2018.11.004

Abstract

Despite successful control in many parts of the world, rabies virus continues to result in tens of thousands of deaths each year. Death from rabies can be prevented by timely and appropriate post exposure prophylaxis including wound cleaning and administration of vaccine and rabies immunoglobulin. Currently, rabies immunoglobulin is derived from the blood plasma of horses or humans and has several limitations relating to supply, cost and quality. Monoclonal antibodies produced through recombinant DNA technologies could potentially overcome these limitations. The first anti-rabies monoclonal antibody has recently gained regulatory approval in India and there are several other candidates being evaluated in clinical trials. Given the advances in the field, rabies monoclonal antibodies have been recently considered by the World Health Organization's Strategic Advisory Group of Experts on Immunization and included in updated WHO immunization policy recommendations for rabies published in April 2018. This article reviews the current landscape of the clinical trial development of anti-rabies monoclonal antibodies and the historical clinical trial pathways followed for blood-derived rabies immunoglobulin before discussing challenges in the clinical evaluation, regulatory approval, uptake and monitoring of these products.

Keywords: Immunoglobulins; Monoclonal antibodies; Passive immunization; Post-exposure prophylaxis; Rabies; Research and development.

PubMed Disclaimer

Cited by

Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy.
Zorzan M, Castellan M, Gasparotto M, Dias de Melo G, Zecchin B, Leopardi S, Chen A, Rosato A, Angelini A, Bourhy H, Corti D, Cendron L, De Benedictis P. Zorzan M, et al. Front Immunol. 2023 Aug 10;14:1186063. doi: 10.3389/fimmu.2023.1186063. eCollection 2023. Front Immunol. 2023. PMID: 37638057 Free PMC article.
A combination of two human monoclonal antibodies cures symptomatic rabies.
de Melo GD, Sonthonnax F, Lepousez G, Jouvion G, Minola A, Zatta F, Larrous F, Kergoat L, Mazo C, Moigneu C, Aiello R, Salomoni A, Brisebard E, De Benedictis P, Corti D, Bourhy H. de Melo GD, et al. EMBO Mol Med. 2020 Nov 6;12(11):e12628. doi: 10.15252/emmm.202012628. Epub 2020 Sep 18. EMBO Mol Med. 2020. PMID: 32945125 Free PMC article.
Efficiency Comparative Approach of Plant-Produced Monoclonal Antibodies against Rabies Virus Infection.
Lumlertdacha B, Mahong B, Rattanapisit K, Bulaon CJI, Hemachudha T, Phoolcharoen W. Lumlertdacha B, et al. Vaccines (Basel). 2023 Aug 17;11(8):1377. doi: 10.3390/vaccines11081377. Vaccines (Basel). 2023. PMID: 37631945 Free PMC article.
Update on lyssaviruses and rabies: will past progress play as prologue in the near term towards future elimination?
Rohde RE, Rupprecht CE. Rohde RE, et al. Fac Rev. 2020 Nov 16;9:9. doi: 10.12703/b/9-9. eCollection 2020. Fac Rev. 2020. PMID: 33659941 Free PMC article. Review.
Development of novel canine phage display-derived neutralizing monoclonal antibody fragments against rabies virus from immunized dogs.
Chorpunkul A, Boonyuen U, Limkittikul K, Saengseesom W, Phongphaew W, Putchong I, Chankeeree P, Theerawatanasirikul S, Hajitou A, Benjathummarak S, Pitaksajjakul P, Lekcharoensuk P, Ramasoota P. Chorpunkul A, et al. Sci Rep. 2024 Oct 3;14(1):22939. doi: 10.1038/s41598-024-73339-2. Sci Rep. 2024. PMID: 39358469 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

001/WHO_/World Health Organization/International

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

Affiliations

Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous